

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Codd et al.

.

Serial No.

10/621,435

: Art Unit

: 1724

Filed

July 17, 2003

:Examiner

: Unassigned

For

BICIFADINE FORMULATION

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. 1.97-1.99, applicants respectfully request that the following references be made of record in the above-identified application:

## **Other Documents**

Epstein et al., "Bicifadine: Non-Narcotic Analgesic Activity of 1-Aryl-3-azabicyclo[3.1.0] hexanes," *NIDA Research Monograph.*, **41:**93-98 (April 1982).

Wang et al., "The Oral Analgesic Efficacy of Bicifadine Hydrochloride in Postoperative Pain," *J. Clin. Pharmacol.*, **22:**160-164 (1982).

Copies of the aforementioned publications are submitted herewith along with a completed form PTO-1449. The references are listed on form PTO-1449. Also enclosed is a copy of the International Search Report dated February 6, 2004.

The above citations do not constitute an admission that the references are relevant or material to the claims; they are cited only as constituting the closest art of which applicant is aware.

## Correspondence and Fees

Pursuant to 37 C.F.R. §1.97(b), since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fees are believed to be necessitated by this Information Disclosure Statement. Should any fee be required, please charge the required fee to Deposit Account No. 03-3839.

Please address all correspondence to Intellectual Property Docket Administrator, Gibbons, Del Deo, Dolan, Griffinger & Vecchione, One Riverfront Plaza, Newark, NJ 07102-5497. Telephone calls should be made to William H. Epstein at (973) 596-4607 and fax communications should be sent directly to her at (973) 639-6397.

Thank you for your consideration.

Date: THE MI

William H. Epstein Attorney for Applicant Registration No. 20,008

Gibbons, Del Deo, Dolan, Griffinger & Vecchione One Riverfront Plaza Newark, New Jersey 07102 (973) 596-4500



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO				Complete if Known			
			OL COURT	Application Number	10/621,435		
INFOR	KMATION L	JIS	CLOSURE	Filing Date	July 17, 2003		
STATI	EMENT RY	΄ Δ	PPLICANT	First Named Inventor	Janet Codd		
יאוט		_	LICAN	Group Art Unit	1724		
	(use as many shee	ets a	s necessary)	Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	102458-40932		

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published.	
		Epstein et al., "Bicifadine: Non-Narcotic Analgesic Activity of 1-Aryl-3-azabicyclo[3.1.0] hexanes," NIDA Research Monograph., 41:93-98 (April 1982).	
		Wang et al., "The Oral Analgesic Efficacy of Bicifadine Hydrochloride in Postoperative Pain," J. Clin. Pharmacol., 22:160-164 (1982).	
der overhoos on market mark market below.	nonconnero con		
	**********************		
to the shirt bridge out 199			
			*****
e werepooned republic and driving	National Security		_

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.